Item 2.02 Results of Operations and Financial Condition.
On March 1, 2022, Quanterix Corporation ("Quanterix" or, the "Company") issued a
press release announcing its financial results for the fourth quarter and year
ended December 31, 2021 and providing a business update (the "Earnings
Release"). A copy of the Earnings Release is furnished as Exhibit 99.1 hereto
and is incorporated herein by reference.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On March 1, 2022, Quanterix announced its executive leadership succession plan
designed to leverage the Company's strong foundation for growth. Effective April
25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become
Executive Chairman of the Board of Directors, and President of Quanterix and
Diagnostics Masoud Toloue will succeed Mr. Hrusovsky as Chief Executive Officer
and join Quanterix' Board of Directors. Mr. Hrusovsky will focus on key
strategic initiatives, Board evolution and important customer, partner and
investor relationships, while transitioning CEO responsibilities to Dr. Toloue.
Additional information about Dr. Toloue, age 41, can be found in the Current
Report on Form 8-K filed by the Company on May 11, 2021 (File No. 001-38319)
which is incorporated herein by reference. A copy of the Press Release
announcing the succession plan is filed as Exhibit 99.2 hereto and is
incorporated herein by reference. An amendment will be filed to this Form 8-K
when the Company has finalized the terms of Mr. Hrusovsky's and Dr. Toloue's
arrangements with the Company.
Item 8.01 Other Events
On March 1, 2022, Quanterix also announced it has entered into a collaboration
with Eli Lilly and Company ("Lilly") to advance the diagnosis, monitoring and
treatment of Alzheimer's disease. As part of the collaboration, Quanterix will
receive a non-exclusive, world-wide license to Lilly's proprietary P-tau217
antibody technology for potential near-term use in research use only products
and services, and future in vitro diagnostic applications. The parties have also
entered into a collaboration agreement, which establishes a framework for future
projects focused on the development of Simoa® immunoassays. As part of this
agreement, Lilly will fund $11 million of development with the Quanterix
Accelerator group this year. A copy of the Press Release announcing the
collaboration with Lilly is filed as Exhibit 99.3 hereto and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Earnings Release dated March 1, 2022.
99.2 Press Release dated March 1, 2022.
99.3 Press Release dated March 1, 2022.
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
The matters reported under Items 5.02 and 8.01 of this Current Report on Form
8-K (including Exhibits 99.2 and 99.3) are being filed pursuant to such items.
The matters reported under Item 2.02 of this Current Report on Form 8-K
(including Exhibit 99.1) are being furnished pursuant to such item and shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that Section, nor shall they be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
© Edgar Online, source Glimpses